Jeroen de Vrij is founder and CEO of ExoVectory and Group Leader Gene Therapy at the Erasmus MC Cancer Institute in the Netherlands. Trained as a gene therapy researcher, he obtained his PhD at Leiden University Medical Center, where he worked on virus-based gene therapy approaches for cancer treatment. Over the past decade, his research has focused on exploring extracellular vesicles (EVs) and Virus Like Particles (VLPs) as tool for delivery of cell and gene therapies. At ExoVectory, this technology is further developed and commercialized as next-generation delivery platform.